<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>QSpace Community:</title>
  <link rel="alternate" href="http://hdl.handle.net/1974/816" />
  <subtitle />
  <id>http://hdl.handle.net/1974/816</id>
  <updated>2013-06-20T01:12:22Z</updated>
  <dc:date>2013-06-20T01:12:22Z</dc:date>
  <entry>
    <title>Characterization of NfxB and PA4596, Two Repressors of the mexCD-oprJ Operon Encoding an RND-Type Multidrug Efflux Pump in Pseudomonas aeruginosa</title>
    <link rel="alternate" href="http://hdl.handle.net/1974/8075" />
    <author>
      <name>PURSSELL, ANDREW</name>
    </author>
    <id>http://hdl.handle.net/1974/8075</id>
    <updated>2013-06-13T05:13:32Z</updated>
    <published>2013-06-12T04:00:00Z</published>
    <summary type="text">Title: Characterization of NfxB and PA4596, Two Repressors of the mexCD-oprJ Operon Encoding an RND-Type Multidrug Efflux Pump in Pseudomonas aeruginosa
Authors: PURSSELL, ANDREW
Abstract: MexCD-OprJ is an RND-type multidrug efflux pump present in P. aeruginosa and is capable of exporting, and as such providing resistance to, several clinically important antimicrobials including fluoroquinolones, cephems, macrolides, and several biocides including chlorhexidine (CHX).  Expression of mexCD-oprJ is negatively regulated by NfxB, a LacI-type repressor.  The promoter region of mexCD-oprJ was identified and included two inverted repeat operator sites, B1 and B2, both of which are required in order for NfxB to bind, thereby repressing mexCD-oprJ.  NfxB oligomerizes into a tetramer in solution and likely functions as a dimer of NfxB homodimers.  In addition to being derepressed by loss of NfxB, MexCD-OprJ is inducible by a variety of non-antibiotic membrane-damaging agents (MDAs) such as CHX.  A homologue of NfxB, PA4596, was found to be induced in response to CHX-promoted envelope stress in an AlgU-dependent manner and is directly repressed by NfxB.  Loss of PA4596 resulted in increased resistance to the biocide CHX, shown to be a result of increased CHX-dependent expression of mexCD-oprJ.  Susceptibility to CHX was restored upon expression of PA4596 from the plasmid pAK1900 as was decreased expression of mexCD-oprJ in the presence of CHX, indicating that PA4596 contributes to mexCD-oprJ repression in the presence of CHX.  PA4596 was found to form oligomers in solution, likely dimers and tetramers.  In the absence of NfxB, PA4596 is unable to contribute to repression of mexCD-oprJ.  However, NfxB and PA4596 interact and together form a repressor capable of regulating mexCD-oprJ expression.  Screening of transposon mutants for increased resistance to erythromycin potentially indicative of increased mexCD-oprJ expression lead to the identification of several novel genes including PA0479, cupA3, faoA, PA3259, mucD, and clpA whose loss generated a multidrug resistance profile consistent with increased production of MexCD-OprJ.  However, further studies are required to determine how each of these genes may be affecting expression of mexCD-oprJ.
Description: Thesis (Ph.D, Microbiology &amp; Immunology) -- Queen's University, 2013-06-12 12:07:28.67</summary>
    <dc:date>2013-06-12T04:00:00Z</dc:date>
  </entry>
  <entry>
    <title>NEU1 SIALIDASE AND MATRIX METALLOPROTEINASE-9 CROSS-TALK IS ESSENTIAL FOR TOLL-LIKE RECEPTOR ACTIVATION AND CELLULAR SIGNALING</title>
    <link rel="alternate" href="http://hdl.handle.net/1974/8007" />
    <author>
      <name>Abdulkhalek, SAMAR</name>
    </author>
    <id>http://hdl.handle.net/1974/8007</id>
    <updated>2013-05-02T04:59:46Z</updated>
    <published>2013-05-01T04:00:00Z</published>
    <summary type="text">Title: NEU1 SIALIDASE AND MATRIX METALLOPROTEINASE-9 CROSS-TALK IS ESSENTIAL FOR TOLL-LIKE RECEPTOR ACTIVATION AND CELLULAR SIGNALING
Authors: Abdulkhalek, SAMAR
Abstract: The molecular mechanism(s) by which Toll-like receptors become activated are not well understood. For the majority of TLR receptors, dimerization is a prerequisite to facilitate MyD88-TLR complex formation and subsequent cellular signaling to activate NF-κB. However, the parameters controlling interactions between the receptors and their ligands still remain poorly defined. Previous reports have identified that neuraminidase-1 (NEU1) is an important intermediate in the initial process of TLR ligand induced receptor activation and subsequent cell function. What we do not yet understand is how NEU1 is activated following TLR ligand binding. In this thesis, the findings disclose a receptor signaling paradigm involving a process of receptor ligand-induced GPCR-signaling via neuromedin-B (NMBR) Gα-proteins, matrix metalloproteinase-9 (MMP-9) activation, and the induction of Neu1 activation. Central to this process is that NEU1–MMP-9-NMBR complex is associated with TLR-4 receptors on the cell surface of naive primary macrophages and TLR-expressing cell lines. Ligand binding to the receptor initiate GPCR-signaling via GPCR Gα subunit proteins and MMP-9 activation to induce NEU1. Activated NEU1 targets and hydrolyzes sialyl α-2-3-linked to β-galactosyl residues at the ectodomain of TLRs, enabling the removal of steric hindrance to receptor association, activation of receptors and cellular signaling.  Furthermore, a novel glycosylation model is uncovered for the activation of nucleic acid sensing intracellular TLR-7 and TLR-9 receptors. It discloses an identical signaling paradigm as described for the cell-surface TLRs. NEU1 and MMP9 cross-talk in alliance with neuromedin-B receptors tethered to TLR-7 and -9 receptors at the ectodomain is essential for ligand activation of the TLRs and pro-inflammatory responses. However, the mechanism(s) behind this GPCR and TLR cross-talk has not been fully defined. Here, GPCR agonists mediate GPCR-signaling via membrane Gα subunit proteins to induce NEU1 and MMP-9 cross-talk at the TLR ectodomain on the cell surface. This molecular organizational GPCR signaling platform is proposed to be an initial processing stage for GPCR agonist-induced transactivation of TLRs and subsequent cellular signaling. Collectively, these novel findings radically redefine the current dogma(s) governing the mechanism(s) of the interaction of TLRs and their ligands, which may provide important pioneering approaches to disease intervention strategies.
Description: Thesis (Ph.D, Microbiology &amp; Immunology) -- Queen's University, 2013-04-30 12:23:42.429</summary>
    <dc:date>2013-05-01T04:00:00Z</dc:date>
  </entry>
  <entry>
    <title>PA5471 modulation of the Pseudomonas aeruginosa mexXY multidrug efflux pump operon repressor MexZ: Identification of important interaction residues and domains</title>
    <link rel="alternate" href="http://hdl.handle.net/1974/7828" />
    <author>
      <name>Hay, Thomas</name>
    </author>
    <id>http://hdl.handle.net/1974/7828</id>
    <updated>2013-02-26T21:41:04Z</updated>
    <published>2013-02-26T05:00:00Z</published>
    <summary type="text">Title: PA5471 modulation of the Pseudomonas aeruginosa mexXY multidrug efflux pump operon repressor MexZ: Identification of important interaction residues and domains
Authors: Hay, Thomas
Abstract: Chemotherapeutic treatment of Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, is substantially challenged by several membrane-spanning, multidrug-efflux pumps of the three-component RND family. Of these pumps, MexXY-OprM contributes to the intrinsic resistance of this organism by exporting clinically relevant antibiotics, most notably the ribosome-targeting aminoglycosides. Overproduction of MexXY-OprM is the most common mechanism providing pan-aminoglycoside resistance to P. aeruginosa cystic fibrosis clinical isolates. The mexXY genes are located in an operon, the expression of which is induced by ribosome-targeting antimicrobials. The mexXY operon is negatively regulated by MexZ, a repressor protein encoded by the divergently-transcribed gene mexZ. A second gene, PA5471, is also induced by ribosome-targeting antibiotics and is required for antibiotic induction of mexXY expression. One possibility is that PA5471 interacts with MexZ to alleviate repression of mexXY, thereby providing a mechanism for PA5471-dependent drug inducibility of mexXY. PA5471 interaction with MexZ was confirmed using a bacterial two-hybrid assay. To identify residues/regions of PA5471 important for interaction with MexZ, random chemical mutagenesis of the mexZ and PA5471 genes was carried out and the effects of these mutations on interaction of their protein products was assessed using the bacterial two-hybrid assay. Mutations of PA5471 that compromised interaction with MexZ included P68S, G76C, R216C, R221W, R221Q, G231D, and G252S, which occur within or in close proximity to a predicted surface-exposed α-helix of a PA5471 structural model that may contribute to the MexZ-interaction domain. Representative mutations P68S, G76C, R216C and R221W were placed into the chromosome of P. aeruginosa to assess their impact on drug-inducible mexXY expression. All of these mutations significantly reduced mexX upregulation in the presence of spectinomycin, where mutations R216C and R221W resulted in the near complete ablation of this antibiotic induction. These data suggest that PA5471 acts as a direct antirepressor of MexZ and that this interaction is key to mexXY upregulation in response to ribosome-targeting induction signals.
Description: Thesis (Master, Microbiology &amp; Immunology) -- Queen's University, 2013-02-26 13:32:39.307</summary>
    <dc:date>2013-02-26T05:00:00Z</dc:date>
  </entry>
  <entry>
    <title>NEURAMINIDASE-1 SIALIDASE AND MATRIX METALLOPROTEINASE-9 CROSSTALK IN ALLIANCE WITH INSULIN RECEPTORS IS AN ESSENTIAL MOLECULAR SIGNALING PLATFORM FOR INSULIN-INDUCED RECEPTOR ACTIVATION</title>
    <link rel="alternate" href="http://hdl.handle.net/1974/7820" />
    <author>
      <name>ALGHAMDI,  FARAH</name>
    </author>
    <id>http://hdl.handle.net/1974/7820</id>
    <updated>2013-02-21T06:12:28Z</updated>
    <published>2013-02-20T05:00:00Z</published>
    <summary type="text">Title: NEURAMINIDASE-1 SIALIDASE AND MATRIX METALLOPROTEINASE-9 CROSSTALK IN ALLIANCE WITH INSULIN RECEPTORS IS AN ESSENTIAL MOLECULAR SIGNALING PLATFORM FOR INSULIN-INDUCED RECEPTOR ACTIVATION
Authors: ALGHAMDI,  FARAH
Abstract: Molecular-targeting therapeutics directed towards growth factor receptors have become promising interventions in cancer. They include the family of mammalian receptor tyrosine kinases such as epidermal growth factor, TrkA and insulin. In particular, the insulin receptor (IR) is one of the most well-known members of the RTK family of receptors playing a role in cancer. IRs are covalently-linked heterodimers of αβ subunits on the cell membrane in the absence of insulin. The IR signaling pathways are initially triggered by insulin binding to the α subunits followed by the interaction of β subunits and ATP. The parameter(s) controlling IR activation remains unknown. Here, we report a membrane receptor signaling platform initiated by insulin binding to its receptor to induce Neu1 in live HTC-IR and MiaPaCa-2 cell lines. Microscopy colocalization and co-immunoprecipitation analyses reveal that Neu1 and MMP9 form a complex with naïve and insulin-treated receptors. Tamiflu (neuraminidase inhibitor), galardin and piperazine (broad range MMP inhibitors), MMP9 specific inhibitor and anti-Neu1 antibody blocked Neu1 activity associated with insulin stimulated live cells. Moreover, Tamiflu, anti-Neu1 antibody, and MMP9 specific inhibitor blocked insulin induced insulin receptor substrate-1 phosphorylation (p-IRS1). The previous findings reveal a molecular organizational signaling platform of Neu1 and MMP-9 crosstalk in alliance with insulin receptors. It proposes that insulin binding to the receptor induces MMP9 to activate Neu1, which hydrolyzes α-2,3 sialic acid in removing steric hindrance to generate a functional receptor. The results predict a prerequisite desialylation process by activated Neu1. A complete understanding of IR activation and the role of sialic acids in the&#xD;
iii&#xD;
signaling pathways may provide a therapeutic strategy in the prevention of different diseases such as diabetes mellitus and cancer.
Description: Thesis (Master, Microbiology &amp; Immunology) -- Queen's University, 2013-02-20 11:27:44.861</summary>
    <dc:date>2013-02-20T05:00:00Z</dc:date>
  </entry>
</feed>

